Antioxidant therapy for chronic hepatitis C after failure of interferon: Results of phase II randomized, double-blind placebo controlled clinical trial

Ezra Gabbay, Ehud Zigmond, Orit Pappo, Nila Hemed, Mina Rowe, George Zabrecky, Robert Cohen, Yaron Ilan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To assess the safety and efficacy of antioxidant therapy for patients with chronic hepatitis C virus (HCV) infection. Methods: One hundred chronic HCV infection patients failed in interferon treatment were enrolled and randomly assigned to receive combined intravenous and oral antioxidants or placebo, or oral treatment alone. Primary end points were liver enzymes, HCV-RNA levels and histology. Results: Combined oral and intravenous antioxidant therapy was associated with a significant decline in ALT levels in 52% of patients who received antioxidant therapy vs 20% of patients who received placebo (P = 0.05). Histology activity index (HAI) score at the end of treatment was reduced in 48% of patients who received antioxidant therapy vs 26% of patients who received placebo (P = 0.21). HCV-RNA levels decreased by 1-log or more in 28% of patients who received antioxidant therapy vs 12% who received placebo (P = NS). In part II of the trial, oral administration of antioxidants was not associated with significant alterations in any of the end points. Conclusion: Antioxidant therapy has a mild beneficial effect on the inflammatory response of chronic HCV infection patients who are non-responders to interferon. Combined antiviral and antioxidant therapy may be beneficial for these patients.

Original languageEnglish
Pages (from-to)5317-5323
Number of pages7
JournalWorld Journal of Gastroenterology
Volume13
Issue number40
DOIs
StatePublished - 28 Oct 2007
Externally publishedYes

Keywords

  • Antioxidant therapy
  • Glycyrrhiza
  • Hepatitis C virus
  • Histology activity index
  • L-glutathione

Fingerprint

Dive into the research topics of 'Antioxidant therapy for chronic hepatitis C after failure of interferon: Results of phase II randomized, double-blind placebo controlled clinical trial'. Together they form a unique fingerprint.

Cite this